Mark Lotter – Founder & CEO, Nuance Biotech, China
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Nuance Biotech (Shanghai) Co. Ltd was founded in 2014. It is Leading China based biotech company focused on commercial, regulatory and development stage assets. Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. It is backed by a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.
Contact
Room 2106 Ciro’s Plaza, 388 Nanjing Rd.(W) Shanghai China, 200003
Tel: 0086 021-32035318
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with…
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he…
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
Juergen Nelis, CEO of BGG World Holding, discusses the company’s strategic growth and evolving approach to sustainability, market expansion, and product innovation. He highlights key initiatives such as expanding production…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to…
See our Cookie Privacy Policy Here
